|
 |
| |
| |
| Licensing & Royalties >> Licensing Opportunities >> Abstract Details |
|
| |
| miR126 for the Mobilization of Hematopoietic Stem/Progenitor Cells (HSPCs) into Peripheral Blood |
Description of Invention:
The NIH inventors have discovered that a micro RNA, miR126, mobilizes hematopoietic stem/progenitor cells (HSPCs) from the bone marrow into blood. These mobilized HSPCs can be easily collected from blood and used for reconstitution of ablated or functionally-impaired bone marrow. miR126 may also facilitate mobilization of bone-resident cancer cells into the circulation where they could be more easily targeted by cancer therapeutics. This discovery could replace bone marrow transplantation as we do it today. Rather than using the current non-selective agent G-CSF (which preferentially mobilizes mature myeloid cells rather than stem/progenitor cells), miR126 could be used for selective mobilization of the HSPCs needed for hematopoietic cell transplantation. Additionally, miR126 could be used to mobilize malignant cells from the bone marrow and render them more easy targets for therapy. It was previously shown that the bone marrow cavity promotes the survival of many cells including tumor cells, and that such cells may easily die when removed from the bone marrow niche and moved to the blood. Therefore, this discovery could also change treatment of many cancers that arise within the bone marrow or metastasize to the bone. Since the mechanism by which miR126 promotes HSPCs/tumor cell mobilization is attributable to the inhibition of VCAM-1 expression, miR126 could be used to treat inflammatory states where the expression of VCAM1 provides an anchor for inflammatory cells at sites of inflammation.
Applications:
- Method of mobilizing hematopoietic stem/progenitor cells (HSPCs) from the bone marrow to the blood
- Use in hematopoietic cell transplantation and treatment of hematopoietic deficiency, hematological failure, and cancer treatments
- To mobilize cancer cells from the bone marrow and thus serve as adjuvant cancer therapy
- As an anti-inflammatory agent to reduce inflammatory cell infiltrates at sites of inflammation
Advantages:
Mobilization of HSPCs yielding high-level, selective and rapid mobilization of HSPCs to the peripheral blood.
Development Status:
- Pre-clinical
- In vivo data available (animal)
Inventors:
Giovanna Tosato (NCI)
Ombretta Salvucci (NCI)
Patent Status:
HHS, Reference No. E-197-2011/0
PCT, Application No. PCT/US2012/000472 filed 03 Oct 2011
Relevant Publication:
- Salvucci O, et al. [PMID 22271895]
Collaborative Research Opportunity:
The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize miR126 and Mobilization of Hematopoietic Stem/Progenitor Cells. For collaboration opportunities, please contact John Hewes, Ph.D. at hewesj@mail.nih.gov. Click here to view the NCI collaborative opportunity announcement.
For Licensing Information Please Contact:
Yolanda Hawkins Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: hawkinsy@mail.nih.gov
Phone: 301-435-5170
Fax: 301-402-0220
Ref No: 2378
Updated: 03/2012
|
|
|
|
| |
|
|
|
|